These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 7629800)
21. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue. Yokel RA; Fredenburg AM; Durbin PW; Xu J; Rayens MK; Raymond KN J Pharm Sci; 2000 Apr; 89(4):545-55. PubMed ID: 10737916 [TBL] [Abstract][Full Text] [Related]
23. The efficacy of DFO-HOPO, DTPA-DX and DTPA for enhancing the excretion of plutonium and ameriicum from the rat. Stradling GN; Gray SA; Moody JC; Hodgson A; Raymond KN; Durbin PW; Rodgers SJ; White DL; Turowski PN Int J Radiat Biol; 1991 May; 59(5):1269-77. PubMed ID: 1675243 [TBL] [Abstract][Full Text] [Related]
24. Specific sequestering agents for the actinides: 10. Enhancement of 238Pu elimination from mice by poly(catechoylamide) ligands. Durbin PW; Jeung N; Jones ES; Weitl FL; Raymond KN Radiat Res; 1984 Jul; 99(1):85-105. PubMed ID: 6547538 [TBL] [Abstract][Full Text] [Related]
25. Effective mitigation of gadolinium deposition using the bidentate hydroxypyridinone ligand Me-3,2-HOPO. Sun Q; Wang X; Shi C; Guan J; Chen L; Wang Y; Wang S; Diwu J Dalton Trans; 2022 Aug; 51(34):13055-13060. PubMed ID: 35971987 [TBL] [Abstract][Full Text] [Related]
26. Early chelation therapy for injected Pu-238 and Am-241 in the rat: comparison of 3,4,3-LIHOPO, DFO-HOPO, DTPA-DX, DTPA and DFOA. Volf V; Burgada R; Raymond KN; Durbin PW Int J Radiat Biol; 1993 Jun; 63(6):785-93. PubMed ID: 8100266 [TBL] [Abstract][Full Text] [Related]
27. From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. An DD; Kullgren B; Jarvis EE; Abergel RJ Chem Biol Interact; 2017 Apr; 267():80-88. PubMed ID: 27038878 [TBL] [Abstract][Full Text] [Related]
28. Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions. Kullgren B; Jarvis EE; An DD; Abergel RJ Toxicol Mech Methods; 2013 Jan; 23(1):18-26. PubMed ID: 22957518 [TBL] [Abstract][Full Text] [Related]
29. Hexadentate hydroxypyridonate iron chelators based on TREN-Me-3,2-HOPO: variation of cap size. Xu J; O'Sullivan B; Raymond KN Inorg Chem; 2002 Dec; 41(25):6731-42. PubMed ID: 12470069 [TBL] [Abstract][Full Text] [Related]
30. (238)Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice. An DD; Villalobos JA; Morales-Rivera JA; Rosen CJ; Bjornstad KA; Gauny SS; Choi TA; Sturzbecher-Hoehne M; Abergel RJ Int J Radiat Biol; 2014 Nov; 90(11):1055-61. PubMed ID: 24937372 [TBL] [Abstract][Full Text] [Related]
31. Highly luminescent and stable hydroxypyridinonate complexes: a step towards new curium decontamination strategies. Sturzbecher-Hoehne M; Kullgren B; Jarvis EE; An DD; Abergel RJ Chemistry; 2014 Aug; 20(32):9962-8. PubMed ID: 25043376 [TBL] [Abstract][Full Text] [Related]
32. Specific Sequestering Agents for the Actinides. 29. Stability of the Thorium(IV) Complexes of Desferrioxamine B (DFO) and Three Octadentate Catecholate or Hydroxypyridinonate DFO Derivatives: DFOMTA, DFOCAMC, and DFO-1,2-HOPO. Comparative Stability of the Plutonium(IV) DFOMTA Complex(1). Whisenhunt DW; Neu MP; Hou Z; Xu J; Hoffman DC; Raymond KN Inorg Chem; 1996 Jul; 35(14):4128-4136. PubMed ID: 11666621 [TBL] [Abstract][Full Text] [Related]
33. Folding Dynamics of 3,4,3-LI(1,2-HOPO) in Its Free and Bound State with U Wang Q; Liu Z; Song YF; Wang D Molecules; 2022 Nov; 27(23):. PubMed ID: 36500244 [TBL] [Abstract][Full Text] [Related]
34. Circulatory kinetics of intravenously injected 238Pu(IV) citrate and 14C-CaNa3-DTPA in mice: comparison with rat, dog, and reference man. Durbin PW; Kullgren B; Schmidt CT Health Phys; 1997 Feb; 72(2):222-35. PubMed ID: 9003707 [TBL] [Abstract][Full Text] [Related]
36. Molecular dynamics simulations of plutonium binding and its decorporation from the binding-cleft of human serum transferrin. Mishra L; Sundararajan M; Bandyopadhyay T J Biol Inorg Chem; 2020 Mar; 25(2):213-231. PubMed ID: 31980924 [TBL] [Abstract][Full Text] [Related]
37. Chelation therapy with 3,4,3-Li(1,2-HOPO) after pulmonary exposure to plutonium in rats. Grémy O; Devilliers K; Miccoli L Chem Biol Interact; 2023 Jun; 378():110488. PubMed ID: 37054935 [TBL] [Abstract][Full Text] [Related]
38. Removal of Pu and am from beagles and mice by 3,4,3-LICAM(C) or 3,4,3-LICAM(S). Lloyd RD; Bruenger FW; Mays CW; Atherton DR; Jones CW; Taylor GN; Stevens W; Durbin PW; Jeung N; Jones ES Radiat Res; 1984 Jul; 99(1):106-28. PubMed ID: 6547537 [TBL] [Abstract][Full Text] [Related]
39. Synthesis of a ligand based upon a new entry into the 3-hydroxy-N-alkyl-2(1H)-pyridinone ring system and thermodynamic evaluation of its gadolinium complex. Johnson AR; O'Sullivan B; Raymond KN Inorg Chem; 2000 Jun; 39(12):2652-60. PubMed ID: 11197022 [TBL] [Abstract][Full Text] [Related]
40. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators. Abergel RJ; Raymond KN Hemoglobin; 2011; 35(3):276-90. PubMed ID: 21599440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]